Alto Neuroscience Files 8-K Report

Ticker: ANRO · Form: 8-K · Filed: 2025-06-26T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Alto Neuroscience filed an 8-K on 6/26/25. Check for updates.

AI Summary

On June 26, 2025, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific material events or financial details beyond the filing type and date were disclosed in the provided text.

Why It Matters

This filing indicates that Alto Neuroscience is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a routine procedural document without immediate disclosed material impact.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Alto Neuroscience, Inc.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as of June 26, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is June 26, 2025.

What is Alto Neuroscience, Inc.'s SEC File Number?

Alto Neuroscience, Inc.'s SEC File Number is 001-41944.

Where are Alto Neuroscience, Inc.'s principal executive offices located?

Alto Neuroscience, Inc.'s principal executive offices are located at 650 Castro St, Suite 450, Mountain View, CA 94041.

What is the telephone number for Alto Neuroscience, Inc.?

The telephone number for Alto Neuroscience, Inc. is (650) 200-0412.

From the Filing

0001999480-25-000053.txt : 20250626 0001999480-25-000053.hdr.sgml : 20250626 20250626074043 ACCESSION NUMBER: 0001999480-25-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250626 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250626 DATE AS OF CHANGE: 20250626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 251075077 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 8-K 1 alto-20250626.htm 8-K alto-20250626 0001999480 False 0001999480 2025-06-26 2025-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 _____________________ ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware   001-41944 83-4210124 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 650 Castro St, Suite 450 , Mountain View , CA 94041 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 650 ) 200-0412 N/A (Former name or former address, if changed since last report.) _____________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ANRO New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 8.01 Other Events. On June 26, 2025, Alto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01    Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Alto Neuroscience, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. D

View on Read The Filing